$506.92 Million in Sales Expected for Bruker Co. (BRKR) This Quarter
Equities analysts forecast that Bruker Co. (NASDAQ:BRKR) will post $506.92 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Bruker’s earnings, with estimates ranging from $504.60 million to $508.90 million. Bruker reported sales of $470.30 million in the same quarter last year, which indicates a positive year-over-year growth rate of 7.8%. The firm is expected to issue its next quarterly earnings report on Monday, February 12th.
According to Zacks, analysts expect that Bruker will report full year sales of $506.92 million for the current year, with estimates ranging from $1.74 billion to $1.75 billion. For the next fiscal year, analysts expect that the company will post sales of $1.82 billion per share, with estimates ranging from $1.78 billion to $1.84 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Bruker.
Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. The company had revenue of $435.60 million for the quarter, compared to the consensus estimate of $415.45 million. Bruker had a return on equity of 25.83% and a net margin of 8.85%. Bruker’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 earnings per share.
Shares of Bruker (NASDAQ:BRKR) opened at $36.22 on Tuesday. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $5,620.00, a price-to-earnings ratio of 38.53, a price-to-earnings-growth ratio of 2.71 and a beta of 1.12. Bruker has a 12-month low of $21.83 and a 12-month high of $36.53.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 22nd. Stockholders of record on Monday, December 4th were given a $0.04 dividend. The ex-dividend date was Friday, December 1st. This represents a $0.16 annualized dividend and a dividend yield of 0.44%. Bruker’s dividend payout ratio is currently 17.02%.
Several large investors have recently modified their holdings of the company. Acrospire Investment Management LLC increased its stake in Bruker by 496.1% in the second quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 3,185 shares during the last quarter. SG Americas Securities LLC acquired a new position in Bruker in the second quarter valued at $111,000. Zions Bancorporation acquired a new position in Bruker in the third quarter valued at $119,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Bruker by 11.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after purchasing an additional 467 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Bruker by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after purchasing an additional 331 shares during the last quarter. Institutional investors and hedge funds own 65.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/09/506-92-million-in-sales-expected-for-bruker-co-brkr-this-quarter.html.
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.